Tuyển tập báo cáo các nghiên cứu khoa học quốc tế ngành y học dành cho các bạn tham khảo đề tài: Improved generation of anti-tumor immunity by antigen dose limitation. | Journal of Immune Based Therapies and Vaccines BioMed Central Original research Improved generation of anti-tumor immunity by antigen dose limitation Joshua D Shofner1 Juan G Vasquez1 Carole L Berger 1 and Richard L Edelson1 2 Open Access Address Department of Dermatology Yale University 333 Cedar Street New Haven CT USA and 2Yale Comprehensive Cancer Center Yale University 333 Cedar Street New Haven CT USA Email Joshua D Shofner - Juan G Vasquez - Carole L Berger - Richard L Edelson - redelson@ Corresponding author Published 9 February 2007 Received 18 October 2006 Journal of Immune Based Therapies and Vaccines 2007 5 2 doi l 476-8518-5-2 Accepted 9 February 2007 This article is available from http content 5 1 2 2007 Shofner et al licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License http licenses by which permits unrestricted use distribution and reproduction in any medium provided the original work is properly cited. Abstract Background The malignant cells of cutaneous T cell lymphoma CTCL display immunogenic peptides derived from the clonal T cell receptor TCR providing an attractive model for refinement of anti-tumor immunization methodology. To produce a clinically meaningful anti-tumor response induction of cytotoxic anti-CTCL cells must be maximized while suppressive T regulatory cells Treg should be minimized. We have demonstrated that engulfment of apoptotic CTCL cells by dendritic cells DC can lead to either CD8 anti-CTCL responses or immunosuppressive Treg induction. Treg generation is favored when the number of apoptotic cells available for ingestion is high. Methods In this study we sought to determine whether the balance between immunity and immunosuppression could be shifted towards a CD8 anti-CTCL response by lowering the ratio of apoptotic .
